There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Werewolf Therapeutics (HOWL – Research Report) and Exelixis (EXEL – Research Report) with bullish sentiments.
Light Up your Portfolio with Spark:
Werewolf Therapeutics (HOWL)
In a report released yesterday, Michael Pachter from Wedbush reiterated a Buy rating on Werewolf Therapeutics, with a price target of $8.00. The company’s shares closed last Wednesday at $1.23, close to its 52-week low of $1.03.
According to TipRanks.com, Pachter is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -5.0% and a 43.6% success rate. Pachter covers the NA sector, focusing on stocks such as Doubledown Interactive Co, Playtika Holding, and Electronic Arts.
Currently, the analyst consensus on Werewolf Therapeutics is a Strong Buy with an average price target of $9.25, implying a 622.7% upside from current levels. In a report issued on March 11, H.C. Wainwright also reiterated a Buy rating on the stock with a $15.00 price target.
See today’s best-performing stocks on TipRanks >>
Exelixis (EXEL)
In a report released today, Gregory Renza from RBC Capital maintained a Buy rating on Exelixis, with a price target of $40.00. The company’s shares closed last Wednesday at $37.20, close to its 52-week high of $40.02.
According to TipRanks.com, Renza is a 4-star analyst with an average return of 6.8% and a 41.5% success rate. Renza covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, Verrica Pharmaceuticals, and Pacira Pharmaceuticals.
Currently, the analyst consensus on Exelixis is a Moderate Buy with an average price target of $37.82, a 2.1% upside from current levels. In a report released today, Truist Financial also maintained a Buy rating on the stock.
Read More on HOWL:
Questions or Comments about the article? Write to editor@tipranks.com